Director of Rapt Therapeutics, Inc. (NASDAQ:RAPT), Robbins Wendye, buys 500 shares worth $8,045
According to Rapt Therapeutics, Inc.'s most recent Statement Of Changes In Beneficial Ownership - Form 4 filing with the SEC dated Nov 23 02:01 PM, company Director, Robbins Wendye disclosed buying 500 shares at a cost of $16.09. At the time of this transaction (Nov 19), this trade was worth $8,045 in total. As of Nov 19, Robbins Wendye now owns 500 shares in total worth about $8,990.0.
For the last few recent trades made by Rapt Therapeutics, Inc. (NASDAQ:RAPT) Director, Robbins Wendye, we have the following information:
- SEC Form 4 filing: Sep 23: Bought 400 shares at the rate of $29.20 per share. Total worth of this trade was $11,680. Total number of shares owned as of Sep 23 were 5,850
- SEC Form 4 filing: Sep 24: Bought 200 shares at the rate of $28.00 per share. Total worth of this trade was $5,600. Total number of shares owned as of Sep 24 were 6,050
- SEC Form 4 filing: Jul 24: Bought 900 shares at the rate of $22.47 per share. Total worth of this trade was $20,225. Total number of shares owned as of Jul 24 were 5,450
Posted by
George Daniels
on Monday November 23 2020, 6:01 PM EDT.
All trademarks acknowledged.
Filed under Business, Stocks.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
